Evidence map›Paper›PMID 31276836›Full record

ArticleJournal of psychiatric research2019

A novel biomarker of cardiometabolic pathology in schizophrenia?

Ellen E Lee, Dorothy D Sears, Jinyuan Liu, Hua Jin, Xin M Tu, Lisa T Eyler, Dilip V Jeste

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of psychiatric research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 16 citations in OpenAlex.

  1. Review
  2. Severe Hypothermia Induces Ferroptosis in Cerebral Cortical Nerve Cells.International journal of molecular sciences · 2024
    Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Ellen E LeeDepartment of Psychiatry, University of California San Diego, La Jolla, CA, USA; Sam and Rose Stein Institute for Research on Aging, University of California San Diego, La Jolla, CA, USA.
Dorothy D SearsDepartment of Medicine, University of California San Diego, USA; Department of Family Medicine and Public Health, University of California San Diego, USA.
Jinyuan LiuSam and Rose Stein Institute for Research on Aging, University of California San Diego, La Jolla, CA, USA; Department of Family Medicine and Public Health, University of California San Diego, USA.
Hua JinDepartment of Psychiatry, University of California San Diego, La Jolla, CA, USA.
Xin M TuDepartment of Psychiatry, University of California San Diego, La Jolla, CA, USA; Sam and Rose Stein Institute for Research on Aging, University of California San Diego, La Jolla, CA, USA; Department of Family Medicine and Public Health, University of California San Diego, USA.
Lisa T EylerDepartment of Psychiatry, University of California San Diego, La Jolla, CA, USA; Desert-Pacific Mental Illness Research Education and Clinical Center, Veterans Affairs San Diego Healthcare System, San Diego, CA, USA.
Dilip V JesteDepartment of Psychiatry, University of California San Diego, La Jolla, CA, USA; Sam and Rose Stein Institute for Research on Aging, University of California San Diego, La Jolla, CA, USA; Center for Healthy Aging, University of California San Diego, La Jolla, CA, USA; Department of Neurosciences, University of California San Diego, La Jolla, CA, USA. Electronic address: djeste@ucsd.edu.
University of California, San Diego · USInstitute on Aging · US

Funding

UC San Diego Clinical and Translational Research InstituteUL1TR001442 · NCATS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI FIRESTEIN, GARY S, HOGARTH, MICHAEL · 2015 to 2024
$88.3M
FELLOWSHIP IN GERIATRIC MENTAL HEALTHT32MH019934 · NIMH · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Elizabeth W Twamley · 1994 to 2026
$9.5M
Accelerated Inflammaging in SchizophreniaR01MH094151 · NIMH · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI EYLER, LISA T · 2012 to 2021
$7.4M
Inflammatory Mechanisms Linking Sleep Disturbances and Cognitive Deficits in Schizophrenia in Later LifeK23MH119375 · NIMH · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI LEE, ELLEN EUN-OK · 2019 to 2023
$1.0M
NCATS NIH HHS UL1 TR001442NIMH NIH HHS K23 MH119375NIMH NIH HHS R01 MH094151NIMH NIH HHS T32 MH019934
6 · The paper itself

Abstract

backgroundPersons with schizophrenia and schizoaffective disorder (PwS) have high rates of cardiometabolic pathology that contributes to premature mortality. Adiponectin is a metabolic hormone affecting insulin sensitivity and inflammation, and is active in the brain. High-molecular weight (HMW) adiponectin is considered a more sensitive marker of metabolic dysfunction than total adiponectin, but has been poorly studied in schizophrenia.

methodsThis was a cross-sectional study of 100 PwS, age range 26-68 years (46 women), and 93 age- and sex-comparable non-psychiatric comparison (NC) subjects. Assessments included measures of psychopathology, physical health, cognitive function, and circulating biomarkers of metabolic dysfunction (HMW adiponectin, lipids, insulin resistance) and inflammation (high-sensitivity C-reactive protein or hs-CRP, Tumor Necrosis Factor-α, Interleukin-6, and Interleukin-10).

resultsHMW adiponectin levels were lower in PwS compared to NCs. Lower HMW adiponectin levels were associated with higher body mass index (BMI), higher Framingham risk for coronary heart disease, higher number of metabolic syndrome criteria, greater insulin resistance, lower HDL cholesterol, and higher hs-CRP in both groups. Only in PwS, lower HMW adiponectin correlated with younger age. In the best-fit regression models of HMW adiponectin, lower levels were associated with lower HDL cholesterol and minority race/ethnicity in both groups; but with younger age, non-smoking, higher insulin resistance, and a diagnosis of schizoaffective disorder only among PwS, and with male sex, better cognitive functioning, and higher hs-CRP levels in NCs only. DISCUSSION: HMW adiponectin may be a promising biomarker of cardiometabolic health, especially among PwS. Adiponectin is a potential target for lifestyle and pharmacological interventions. Research on the possible role of HMW adiponectin in modifying cardiometabolic pathology in schizophrenia is needed.

Indexed as

AdiponectinAdultAgedBiomarkersCardiovascular DiseasesCross-Sectional StudiesFemaleHumansMaleMetabolic SyndromeMiddle AgedMolecular WeightPsychotic DisordersSchizophreniaAdiponectinADIPOQ protein, humanBiomarkersAdipokinesAgingBody mass indexCytokinesHemoglobin A1CInsulin resistance

Identifiers

PMID31276836
PMCPMC6707833
OpenAlexW2949412502

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.